治疗顺序是否会影响化生性乳腺癌患者的结局？
Does treatment sequence affect outcomes in patients with metaplastic breast cancer?
机构信息
Department of Surgery, Duke University Medical Center, Box 3513, Durham, NC, 27710, USA.
Biostatistics Shared Resource, Duke Cancer Institute, Durham, NC, 27710, USA.
出版信息
Am J Surg. 2021 Apr;221(4):701-705. doi: 10.1016/j.amjsurg.2021.01.007. Epub 2021 Jan 18.
INTRODUCTION
We compared characteristics and outcomes by treatment sequence among patients with metaplastic breast cancer (MBC), an aggressive subtype.
METHODS
Women ≥18 years old with newly diagnosed Stage I-III MBC from 2003 to 2018 who received any treatment in our health system were identified. Unadjusted overall survival (OS) was estimated with the Kaplan-Meier method; the log-rank test was used to compare survival differences between recipients of neoadjuvant (NACT) and adjuvant chemotherapy (ACT).
RESULTS
Of the 91 MBC patients identified, 60 received chemotherapy. NACT recipients (n = 20, median age 46.5 y) were younger than ACT recipients (n = 40, median age 60.5 y, p < 0.001) but similar with regards to race and radiation receipt. There was no significant OS difference between NACT and ACT recipients (log-rank p = 0.15), which remained true when patients were stratified by age (≥50 y vs < 50 y).
CONCLUSIONS
Among MBC patients, NACT recipients were younger than ACT recipients, but there was no survival difference by treatment sequence.
介绍
我们比较了具有转移性乳腺癌（MBC）的患者在不同治疗顺序下的特征和结局，MBC 是一种侵袭性亚型。
方法
本研究纳入了 2003 年至 2018 年间在我们医疗系统中诊断为 I-III 期 MBC 且年龄≥18 岁的女性患者。采用 Kaplan-Meier 法估计未经调整的总生存（OS）；采用对数秩检验比较接受新辅助化疗（NACT）和辅助化疗（ACT）的患者的生存差异。
结果
在 91 例 MBC 患者中，有 60 例接受了化疗。NACT 组（n=20，中位年龄 46.5 岁）患者的年龄小于 ACT 组（n=40，中位年龄 60.5 岁，p<0.001），但两组在种族和放疗方面相似。NACT 组和 ACT 组之间的 OS 差异无统计学意义（对数秩检验 p=0.15），当按年龄（≥50 岁与<50 岁）分层时，该结果仍然成立。
结论
在 MBC 患者中，NACT 组患者的年龄小于 ACT 组患者，但治疗顺序无生存差异。
Zotero 插件